Level Up

SLAS2020 Short Courses

An Introduction to Mass Spectrometry and its Applications within Drug Discovery

This short course will provide an introduction to mass spectrometry and the range of potential applications within drug discovery. We will cover the basic principles of mass spectrometry, including the differences between the array of ionization modalities and detectors available today. While mass spectrometry has contributed significantly to drug discovery, recent advances are enabling high throughput screening applications.

Who Should Attend

  • Lab scientists with an interest in understanding the fundamentals of mass spectrometry
  • Lab managers interested in understanding how mass spectrometry can impact drug discovery
  • Budget holders who are considering investing in mass spectrometry technology
  • Assay development scientists and HTS screeners who want to understand how mass spectrometry can impact their research

Course Benefits

  • Get a better understanding of the principles of mass spectrometry
  • Gain an understanding of the diversity of instruments and ionization techniques
  • Understand where mass spectrometry can be applied with impact in drug discovery
  • Learn about recent developments in mass spectrometry

Course Topics

  • Basic principles of mass spectrometry
  • Overview of ionization modalities and mass detectors
  • Introduction to separation techniques and matrix effects
  • Electrospray platforms for HTS applications
  • MALDI applications in drug discovery
  • Overview of MS imaging
  • Recent advances in MS technology and impact in drug discovery

Instructors:

Jonathan Wingfield

Jonathan Wingfield, Ph.D.
AstraZeneca, Discovery Sciences

Jonathan Wingfield, Ph.D., has nearly 20 years’ experience of assay development and automation of high throughput screening for drug discovery within pharma. Wingfield joined AstraZeneca (AZ) in 2000 to deliver technology solutions that support pre-clinical screening within the oncology disease area. He established a centralized biochemical screening group which went on to receive the 2008 Microsoft Innovation in Pharma Award. He’s was also involved in the deployment of acoustic technology within AZ, which ultimately lead to a SLAS 2015 Innovation Award winning project investigating the integration of an acoustic source as a loading system for mass spectrometry.

Paul Davey

Paul Davey, Ph.D.
AstraZeneca, Discovery Sciences

Paul Davey, Ph.D., graduated from Sheffield Hallam University with a B.Sc. in biomedical chemistry where he received an RSC prize in analytical science and carried out a year’s training within the pharmacy division of Glaxo Welcome. After Glaxo, Davey moved to the United States and studied under professor A.P. Marchand at the University of North Texas (Denton) carrying out the synthesis of polycyclic oxiranes for potential use in military applications. He then joined Huntingdon Life Sciences as a new graduate in the mass spectrometry department carrying out the quantitative analysis of metabolites and small molecule drugs in biological fluids. He became a field-based service engineer working on new time of flight technology for Waters Micromass in 1999.

Davey joined AstraZeneca as a spectrometrist supporting technology in 2001, and aided the introduction of open access LCMS, orthogonal chromatography and UPLC MS into all the research areas. He then moved into the analytical and structural chemistry group in 2007 and received training in structural elucidation by mass spectrometry and NMR. In 2010 he was made a senior research scientist and operated the mass spectrometry group alone after the retirement of the previous incumbent.

After incorporating new electronic reporting and sample tracking system as well as global data storage initiatives. In 2014, Davey helped co-ordinate the move of the analytical group to Cambridge by aiding the design of the MS hub laboratory in the CBC new build.

As a member of the ASC group Davey has continued to deepen and broaden his LC-MS skill set supporting multiple groups and different oncology projects, in particular, the development of a novel intracellular concentration assay as well as new approaches to protein binding, reaction rate measurement and stability testing.

To date, he has supported and co-authored fourteen peer review papers which have been published in various journals, including Nucleic Acids Research, the Journal of Medicinal Chemistry and Scientific Reports.


Our Sponsors

Premier Sponsor:
Hamilton

  • Diamond Sponsor

    Artel
  • Diamond Sponsor

    Beckman Coulter
  • Diamond Sponsor

    Corning
  • Diamond Sponsor

    Miltenyi Biotek
  • Diamond Sponsor

    Scinomix
  • Diamond Sponsor

    Thermo Fisher Scientific
  • Platinum Sponsor

    BMG Labtech
  • Platinum Sponsor

    Broooks Life Sciences
  • Platinum Sponsors

    Cosmo Technologies
  • Platinum Sponsor

    Hamamatsu
  • Platinum Sponsor

    Molecular Devices
  • Platinum Sponsor

    Tecan
  • Gold Sponsor

    Agilent
  • Gold Sponsor

    Biotek
  • Gold Sponsor

    Inheco
  • Gold Sponsor

    Waters
  • Silver Sponsor

    ACS Combinatorial Science
  • Silver Sponsor

    Analytik Jena
  • Silver Sponsor

    Greiner Bio-One
  • Silver Sponsor

    SAMDI
  • Media Partner

    The Analytical Scientist
  • Media Partner

    Biocompare
  • Media Partner

    Cell Press
  • Media Partner

    CLP
  • Media Partner

    DDN News
  • Media Partner

    DDW
  • Media Partner

    DTR
  • Media Partner

    GEN News
  • Media Partner

    Lab Manager
  • Media Partner

    LRIG
  • Media Partner

    Science AAAS
  • Media Partner

    Europa Science/Scientific Computing World
  • Media Partner

    Select Science
  • Media Partner

    Technology Networks
  • Media Partner

    The Scientist